Brief: Ose Immunotherapeutics Announces New Us Patent Granted For Tedopi®
05/07/2023 09:51
July 4 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* ANNOUNCED ON TUESDAY NEW US PATENT GRANTED FOR USE OF
TEDOPI® IN
CANCER PATIENTS AFTER FAILURE WITH PD-1/PD-L1 IMMUNE CHECKPOINT
INHIBITOR TREATMENT
* NEW PATENT FURTHER IMPROVES UNIQUE VALUE PROPOSITION OF
TEDOPI®
AND PROVIDES PROTECTION UNTIL YEAR 2037 IN US
Source text for Eikon: ID:nBwbypS2Ya
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO